REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

doi:10.1126/science.abe2402

GSTDTAP > 气候变化

DOI	10.1126/science.abe2402
	REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
	Alina Baum; Dharani Ajithdoss; Richard Copin; Anbo Zhou; Kathryn Lanza; Nicole Negron; Min Ni; Yi Wei; Kusha Mohammadi; Bret Musser; Gurinder S. Atwal; Adelekan Oyejide; Yenny Goez-Gazi; John Dutton; Elizabeth Clemmons; Hilary M. Staples; Carmen Bartley; Benjamin Klaffke; Kendra Alfson; Michal Gazi; Olga Gonzalez; Edward Dick; Ricardo Carrion; Laurent Pessaint; Maciel Porto; Anthony Cook; Renita Brown; Vaneesha Ali; Jack Greenhouse; Tammy Taylor; Hanne Andersen; Mark G. Lewis; Neil Stahl; Andrew J. Murphy; George D. Yancopoulos; Christos A. Kyratsous
	2020-11-27
发表期刊	Science
出版年	2020
英文摘要	Since the start of the coronavirus disease 2019 (COVID-19) pandemic, considerable effort has gone into generating and characterizing neutralizing antibodies that could be used as therapeutics. Studies in humanized mice and convalescent humans led to the development of a cocktail of two potent antibodies that simultaneously bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prevent the virus from entering host cells. Baum et al. evaluated the efficacy of this cocktail, REGN-COV2, in rhesus macaques, which may model mild disease, and in golden hamsters, which present more severe symptoms. The antibody cocktail provided benefits in both models when administered either prophylactically or therapeutically and is currently in clinical trials. Science , this issue p. [1110][1] An urgent global quest for effective therapies to prevent and treat coronavirus disease 2019 (COVID-19) is ongoing. We previously described REGN-COV2, a cocktail of two potent neutralizing antibodies (REGN10987 and REGN10933) that targets nonoverlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. In this report, we evaluate the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model mild disease, and golden hamsters, which may model more severe disease. We demonstrate that REGN-COV-2 can greatly reduce virus load in the lower and upper airways and decrease virus-induced pathological sequelae when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters limits weight loss and decreases lung titers and evidence of pneumonia in the lungs. Our results provide evidence of the therapeutic potential of this antibody cocktail. [1]: /lookup/doi/10.1126/science.abe2402
领域	气候变化 ; 资源环境
URL	查看原文
引用统计	被引频次：331[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/304889
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Alina Baum,Dharani Ajithdoss,Richard Copin,et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters[J]. Science,2020.
APA	Alina Baum.,Dharani Ajithdoss.,Richard Copin.,Anbo Zhou.,Kathryn Lanza.,...&Christos A. Kyratsous.(2020).REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.Science.
MLA	Alina Baum,et al."REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters".Science (2020).